Previous research has shown that another hormone receptor, the androgen receptor, can act as a tumor suppressor in ER+ breast cancer. Activating the androgen receptor has shown promise as a potential treatment strategy, but scientists are still working to understand exactly how it stops cancer cells from growing.
Researchers from Adelaide University’s School of Medicine, the South Australian immunoGENomics Cancer Institute (SAiGENCI) and SAHMRI have now uncovered an important piece of that puzzle.